New analysis shows that more medicines worldwide are available to U.S. patients
By Kevin Haninger | June 5, 2018
In the past year, we have seen revolutionary new treatments become available to patients in the United States for cancer and other debilitating diseases. A new analysis puts in perspective the...
Read More
Spending on medicines grew less than one percent in 2017
By Holly Campbell | April 19, 2018
Last year, a record number of new treatments and cures that are transforming care for patients fighting debilitating diseases like cancer, hepatitis C, high cholesterol and more were approved by...
Read More
Rare Disease Day: Unmet need inspires innovation
By Andrew Powaleny | February 28, 2018
Today, we celebrate Rare Disease Day to both reflect on the progress made toward conquering rare diseases and recognize the continued unmet medical need for these devastating, complex conditions.
Read More
Innovation comes in many forms, including new and expanded uses of existing medicines
By Emma Van Hook | January 29, 2018
2017 was a record-breaking year for new drug approvals, with the U.S. Food and Drug Administration (FDA) approving 56 new drugs and biologics. But the innovation did not stop there. As the FDA...
Read More
ICYMI: Why 2017 medicine approvals matter
By Andrew Powaleny | January 12, 2018
This week, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) released its 2017 New Drug Therapy Approvals report. Last year marked an extraordinary...
Read More
New surveys find payers and providers want more data from biopharmaceutical companies
By Joe Vandigo | December 6, 2017
Both payers and providers are interested in additional information from biopharmaceutical companies about prescription medicines – including information about pipeline medicines and unapproved...
Read More
Supporting opportunities for enhanced competition in the marketplace
By Andrew Powaleny | November 22, 2017
Promoting competition is an important focus for the biopharmaceutical industry. Since 1984, the Hatch-Waxman Act has fostered robust competition through the timely entry of generic medicines into...
Read More
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
By Holly Campbell | October 12, 2017
PhRMA president and CEO Stephen J. Ubl joined Fox Business’ Maria Bartiromo on “Mornings with Maria” today to discuss bold steps the biopharmaceutical industry has taken in the last few months as...
Read More
Opportunities to build upon enhanced competition for medicines in the marketplace
By David Korn | July 27, 2017
Last week, I presented at the U.S Food and Drug Administration’s (FDA) public meeting on the Hatch-Waxman Amendments to discuss the balance between encouraging innovation in biopharmaceutical...
Read More
Why reauthorization of PDUFA matters
By Andrew Powaleny | July 13, 2017
Last night, the Prescription Drug User Fee Act (PDUFA), was reauthorized by the House of Representatives. PDUFA provides the U.S. Food and Drug Administration (FDA) with necessary resources to...
Read More
Medicare Monday (100)
340B Spotlight (35)
Cost & Consequence (0)
